X

Trial Profile

A phase I study of THX-ULD01 for the treatment of mild cognitive impairment

Status: Not yet recruiting

Phase of Trial: Phase I

Latest Information Update: 11 Feb 2022

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs THX-ULD01 (Primary)
Indications Brain injuries; Cognition disorders
Focus Adverse reactions; Proof of concept
Sponsors SciSparc

Most Recent Events

09 Nov 2017 According to a Therapix Biosciences media release, Institutional Review Board approval has been recieved.
09 Nov 2017 Status changed from planning to not yet recruiting, according to a Therapix Biosciences media release.
10 Aug 2017 According to a Therapix Biosciences media release, this study will be initiated in the fourth quarter of 2017.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com